These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 24210913)

  • 1. Re: Christoph A. Von Klot, Markus A. Kuczyk, Axel S. Merseburger. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting. Eur Urol 2014;65:258-9: Enzalutamide withdrawal syndrome: fact or fiction?
    Schrader AJ; Schrader MG; Cronauer MV
    Eur Urol; 2014 Feb; 65(2):e22-3. PubMed ID: 24210913
    [No Abstract]   [Full Text] [Related]  

  • 2. No androgen withdrawal syndrome for enzalutamide: a report of disease dynamics in the postchemotherapy setting.
    von Klot CA; Kuczyk MA; Merseburger AS
    Eur Urol; 2014 Jan; 65(1):258-9. PubMed ID: 24094574
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzalutamide withdrawal syndrome: is there a rationale?
    Mosca A
    BJU Int; 2015 Mar; 115(3):348-9. PubMed ID: 25683877
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prostate cancer - enzalutamide extends survival].
    Aktuelle Urol; 2014 Mar; 45(2):98. PubMed ID: 24818263
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    Shiota M; Yokomizo A
    Eur Urol; 2016 Mar; 69(3):e41-2. PubMed ID: 26215602
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
    van Soest RJ; de Morrée ES; Kweldam CF; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur Urol; 2016 Mar; 69(3):e43-4. PubMed ID: 26233533
    [No Abstract]   [Full Text] [Related]  

  • 7. Is there an anti-androgen withdrawal syndrome for enzalutamide?
    von Klot CA; Kramer MW; Böker A; Herrmann TR; Peters I; Kuczyk MA; Ligges U; Gschwend JE; Retz M; Schmid SC; Stenzl A; Schwentner C; Todenhöfer T; Stöckle M; Ohlmann CH; Azone I; Mager R; Bartsch G; Haferkamp A; Heidenreich A; Piper C; Merseburger AS
    World J Urol; 2014 Oct; 32(5):1171-6. PubMed ID: 24691670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug eruption caused by enzalutamide: A case and literature review of androgen receptor inhibitor-related drug eruptions.
    Saito-Sasaki N; Sawada Y; Okada E; Nakamura M
    Australas J Dermatol; 2018 May; 59(2):e133-e134. PubMed ID: 29878315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Word of wisdom. Re: enzalutamide in metastatic prostate cancer before chemotherapy.
    Chow K; Murphy DG
    Eur Urol; 2014 Oct; 66(4):785-6. PubMed ID: 25218073
    [No Abstract]   [Full Text] [Related]  

  • 10. Words of wisdom. Re: Enzalutamide in metastatic prostate cancer before chemotherapy.
    Althaus A; Kibel A
    Eur Urol; 2015 Jan; 67(1):174. PubMed ID: 25528395
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Nader Al Nakouzi, Sylvestre Le Moulec, Laurence Albigès, et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.015.
    van Soest RJ; de Wit R; van Weerden WM
    Eur Urol; 2014 Oct; 66(4):e71-2. PubMed ID: 25012524
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Kimura T; Egawa S
    Eur Urol; 2017 Feb; 71(2):303. PubMed ID: 27597237
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Beer TM; Tombal B
    N Engl J Med; 2014 Oct; 371(18):1755-6. PubMed ID: 25354111
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzalutamide in metastatic prostate cancer before chemotherapy.
    Froehner M; Wirth MP
    N Engl J Med; 2014 Oct; 371(18):1755. PubMed ID: 25354112
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome.
    Phillips R
    Nat Rev Urol; 2014 Jul; 11(7):366. PubMed ID: 24960596
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer: Enzalutamide--differential cross resistance with taxanes.
    Fenner A
    Nat Rev Urol; 2015 Feb; 12(2):64. PubMed ID: 25534993
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzalutamide in prostate cancer after chemotherapy.
    Berruti A; Generali D; Tampellini M
    N Engl J Med; 2012 Dec; 367(25):2448; author reply 2448-9. PubMed ID: 23252532
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostate cancer: enzalutamide PREVAILs.
    Payton S
    Nat Rev Urol; 2014 Jul; 11(7):361. PubMed ID: 24934449
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzalutamide--a major advance in the treatment of metastatic prostate cancer.
    Vogelzang NJ
    N Engl J Med; 2012 Sep; 367(13):1256-7. PubMed ID: 23013078
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Hung-Ming Lam, Holly M. Nguyen, Mark P. Labrecque, et al. Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. Eur Urol 2020;77:144-55.
    Lavorgna G; Montorsi F; Salonia A
    Eur Urol; 2020 Sep; 78(3):e137-e138. PubMed ID: 32527693
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.